|
Christine Clouser is an American virologist. She obtained a Bachelor of Science Degree in Chemistry from St. Cloud State University in Minnesota and obtained her Masters of Science and PhD. in Biological Chemistry from the University of Michigan. During her graduate studies she sparked an interest in retro viruses and has since then published scientific articles on the feline leukemia virus and HIV virus. ==Education and experience== Christine started her undergraduate studies in 1993 and obtained her Bachelors Degree in 1998. She entered graduate school the same year she received her Bachelors Degree. During her graduate studies she completed a dissertation on (the regulation of Lutenizing Hormone Receptor ) an mRNA binding protein. Christine completed her graduate studies in 2006. She obtained a Master of Science and PhD in biological chemistry from the University of Michigan. After completing her graduate studies, Christine moved to Minnesota where she became a Postdoctoral Fellow for the University of Minnesota. In 2014 Christine began teaching as a research assistant professor for the University of Minnesota working side by side with Louis Mansky and Steven Patterson. ==Contributions to virology research== Christine works with Dr. Louis Mansky and Dr. Steven Patterson to investigate antiviral properties of ribonucleoside and nucleoside analogues against the human immunodeficiency virus. In their laboratory model system two nucleoside analogues, Decitabine and Gemcitabine, have been found to cause lethal mutagenesis of the HIV-1 virus when used combination therapy. These two drugs are FDA approved and used interventionally as chemotherapy drugs. When used together, these drugs have been found to have strong antiviral properties against HIV-1 by causing the virus to rapidly mutate, lose virulence factors, and become non infectious.〔(【引用サイトリンク】url=http://www.sciencedaily.com/releases/2013/08/130830143912.htm )〕 There are advantages for using existing pharmaceuticals already approved by the United States Food and Drug Administration for treating conditions with new implications. The development of new pharmaceuticals takes time and very is costly when compared to repositioning of existing drugs. Drug repositioning is simply the application of using known drugs for new purposes. When HIV-1 cells were cultured and investigated in the laboratory, the research team of: Christine Clouser, Louis Mansky, and Steven Patterson, have found a novel combination therapy for rendering the HIV-1 virus harmless by using a combination therapy of two pro drugs Decitabine and Gemcitabine. Christine is anticipating finding a way to deliver both of these drugs in a pill form, as both drugs are currently delivered intravenously and used as treatments for other conditions. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Christine L. Clouser」の詳細全文を読む スポンサード リンク
|